These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29429435)

  • 1. Is there transparency in the pricing of medicines in the South African private sector?
    Bangalee V; Suleman F
    S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
    Naidoo K; Suleman F
    S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].
    Maïga D; Maïga S; Maïga MD
    Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 6. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 7. Public- and private-sector partnerships in contraceptive research and development: guiding principles.
    Brooke S; Vail JG
    Int J Gynaecol Obstet; 1999 Dec; 67 Suppl 2():S125-39. PubMed ID: 10661750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):627-36. PubMed ID: 24953125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014.
    Moodley R; Suleman F
    PLoS One; 2019; 14(7):e0219690. PubMed ID: 31365534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
    Shaw B; Mestre-Ferrandiz J
    Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. March 5: "Global Day of Action against Drug Company Profiteering," as pharmaceutical companies sue South Africa to block low-cost medicines.
    James JS
    AIDS Treat News; 2001 Jan; (359):5-6. PubMed ID: 12173562
    [No Abstract]   [Full Text] [Related]  

  • 12. Pricing in the Market for Anticancer Drugs.
    Howard DH; Bach PB; Berndt ER; Conti RM
    J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702
    [No Abstract]   [Full Text] [Related]  

  • 13. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. South Africa: TAC, COSATU and allies file complaint of excessive pricing.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):63-5. PubMed ID: 14743804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and components analysis of some key essential pediatric medicine in Odisha state.
    Samal S; Swain TR
    Indian J Pharmacol; 2017; 49(1):89-92. PubMed ID: 28458429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promise of South African biotech.
    Akermann B; Kermani F
    Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
    [No Abstract]   [Full Text] [Related]  

  • 18. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
    Sarpatwari A; Kesselheim AS
    J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
    [No Abstract]   [Full Text] [Related]  

  • 19. Pricing and availability of some essential child specific medicines in Odisha.
    Swain TR; Rath B; Dehury S; Tarai A; Das P; Samal R; Samal S; Nayak H
    Indian J Pharmacol; 2015; 47(5):496-501. PubMed ID: 26600637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.